The company in particular seeks 'Rights Issue' to meet its capital requirements.
The company posted a topline growth of Rs2142.87 lakhs, a growth of over 26% yoy.
The packaging lines have received approval from the UK-MHRA (Medicines and Healthcare products Regulatory Agency) for the United Kingdo
The pharma company received renewal certificate from UK MHRA, as per BSE filing.
In its response, the company has stated that the type of securities proposed to be issued are share warrants convertible to equity shar
The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to the announcement dated Jan 9, 2017, informing
A board meeting will be held today to consider withdrawal of entire preferential issue of 40,00,000 share warrants due to inordinate de
The pharma company has received its renewal certificate from Medicines and Healthcare products Regulatory Agency (MHRA), London.
The company has got the renewal certificate from Medicines and Healthcare products Regulatory Agency (MHRA), London.
The stock of the company is up by 12% at Rs. 27.70.
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity